Novo Nordisk's Weight-Loss Drug Sales Surge, Stock Pops on Q4 Earnings Beat
TL;DR Summary
Novo Nordisk reports a 38% growth in demand for its GLP-1 products for diabetes and obesity, but continues to face supply issues with its drug Wegovy in the US due to unrelenting demand, with the FDA still listing it in shortage. The company has doubled its starter doses for Wegovy in the US, but CEO Lars Fruergaard Jørgensen acknowledges that supply will likely remain unsteady for some time due to overwhelming demand that outstrips production capacity.
- Novo Nordisk continues diabetes, obesity sales rise, but still on the back foot with Wegovy supply Endpoints News
- Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic CNBC
- Ozempic Maker Novo Nordisk Beats Profit Forecasts As Weight-Loss Sales Soar Forbes
- Novo Nordisk Begins Gradually Increasing Supply of Blockbuster Weight-Loss Drug Wegovy The Wall Street Journal
- Novo Nordisk stock pops on Q4 earnings beat Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
50%
152 → 76 words
Want the full story? Read the original article
Read on Endpoints News